News

May 7, 2026

Can Turmeric/Curcumin Help With Inflammatory Bowel Disease?

Taking turmeric, either in food or supplement form, is definitely a popular trend these days. This post looks at the evidence supporting its use in managing ulcerative colitis and Crohn’s disease.

Turmeric has been used for centuries in traditional Ayurvedic and Chinese medicine to treat inflammatory disorders. Curcumin is the active substance in the spice turmeric (Curcuma longa) and is what gives it its bright yellow colour. Emerging studies suggest that curcumin can help reduce inflammation, protect cells from damage, and regulate your immune system. These effects may help manage symptoms of inflammatory bowel disease (IBD) when used in combination with standard medical treatment.

Research on curcumin in IBD

Most studies on curcumin and its effects in IBD have been conducted in cell or animal models. In recent years, more studies in humans have been done to better understand its potential benefits.

Ulcerative Colitis (UC) Most studies suggest that curcumin can help people with UC, especially when used alongside standard medications. These studies found that:

●      Moderate to high doses of easy-to-absorb (bio-enhanced) forms of curcumin appear to support gut healing, symptom control, and long-term remission.

●      Bio-enhanced curcumin, combination therapies such as pairing it with Qing Dai (also known as Indigo naturalis, a traditional Chinese medicine used for inflammatory conditions), or lower-intestinal treatments (such as NCB-02, a curcumin enema), showed stronger and more consistent gut benefits.

●      Some studies reported no benefit, particularly with low-dose (such as 450 mg/day) standard natural forms of curcumin, suggesting its effects are dose-dependent. Higher doses (2-3 g/day), however, may provide some benefit.

●      Curcumin seems to work best when combined with standard treatments (e.g., mesalamine or 5-ASA), rather than used alone.

Overall, curcumin appears to be a promising and generally safe add-on therapy for inducing and maintaining remission in mild-to-moderate UC. Its effectiveness, however, depends on dose and formulation.
Crohn’s Disease (CD) There is limited research on the effects of curcumin in Crohn’s disease (CD), with relatively few and small studies available. Some key findings include:

●      Some small studies reported improvements in gut symptoms and higher remission rates.

●      Bio-enhanced curcumin has been shown to promote remission.

●      However, one larger study found no benefit in preventing postoperative IBD recurrence after bowel resection and suggested it may even worsen disease outcomes.

Curcumin may potentially benefit some patients with CD, but the current evidence remains inconclusive. Larger, long-term studies are needed to better understand its role in CD.
Recommended dose of curcumin and length of treatment
  • Standard Curcumin: ~2–3 g per day, taken alongside standard medical treatment for at least 1–2 months.
  • Bio-enhanced Curcumin: At least ~100 mg per day, taken alongside standard treatment for a minimum of 2 months.
Is it safe to take high doses of curcumin?

 Curcumin is generally considered safe, with few reported side effects. Even studies using high doses of curcumin, up to 12g/day, have shown minimal adverse side effects. A small subset of people in studies experienced mild gut symptoms, such as stomach pain, nausea and diarrhea. It should be noted that the studies evaluating the safety of curcumin have been relatively short; long-term studies are lacking.

Newer research suggests that highly absorbable curcumin supplements, including those enhanced with piperine or nanoparticle formulations, rarely cause serious liver injury after weeks to months of use. However, severe liver failure has been reported in rare cases.

Who should not take curcumin?

Furthermore, curcumin supplements may interfere with iron metabolism and should not be taken if you are on blood thinners, such as warfarin. They are also not recommended during pregnancy or breastfeeding. If you are considering curcumin supplements, speak with a doctor or pharmacist to ensure they do not interact with any medications you are taking or worsen existing health conditions.

Curcumin in food versus supplement form

Getting curcumin from turmeric itself is another option and may be safer for long-term use. However, curcumin is not very well-absorbed, and turmeric contains only small amounts of it. For example, one teaspoon of turmeric provides roughly 200 mg of curcumin, meaning you would need to consume large amounts of turmeric to reach the doses used in research studies. That said, the optimal dose of curcumin is still unclear, so using turmeric in cooking may still offer some benefit. Consuming turmeric with black pepper and a source of fat can help improve curcumin absorption.

Reading curcumin supplement labels

If you are considering a curcumin supplement, it’s important to understand how to read the label. When a supplement lists the amount of turmeric (Curcuma longa), only about 2–8% of that amount is curcumin. In contrast, turmeric root extracts are often standardized to contain around 95% curcumin. Many supplements provide between 500 and 1,000 mg of curcumin per serving.

Curcumin Supplements to Consider

Some bio-enhanced curcumin supplements available in Canada that may help improve IBD symptoms include:

If you are interested in trying curcumin supplements, please consult a registered dietitian, pharmacist, or physician to determine if these products are appropriate for you.

Take-Away Points

  • Curcumin supplements may benefit some patients with IBD, particularly when used alongside standard treatments.
  • Suggested dose: Either 2–3 g of Standard Curcumin or 100 mg or more of bio-enhanced Curcumin alongside standard treatment for 1 to 2 months or more.
  • Consuming curcumin in food form, as turmeric, is likely safer than taking concentrated or enhanced supplements, but may be less effective at reducing inflammation.
  • More research is needed to determine the optimal dose, form, and long-term safety of curcumin for IBD.

References:

  1. Banerjee, R., Pal, P., Penmetsa, A., Kathi, P., Girish, G., Goren, I., … Girish, G. (2021). Novel bioenhanced curcumin with mesalamine for induction of clinical and endoscopic remission in mild-to-moderate ulcerative colitis: A randomized double-blind placebo-controlled pilot study. Journal of Clinical Gastroenterology, 55, 702–708. https://doi.org/10.1097/MCG.0000000000001416
  2. Ben-Horin, S., Salomon, N., Karampekos, G., Viazis, N., Lahat, A., Ungar, B., Eliakim, R., Kriger-Sharabi, O., Reiss-Mintz, H., Yanai, H., Dotan, I., Zittan, E., Hirsch, A., Maharshak, N., Mantzaris, G., & Kopylov, U. (2023). Curcumin-QINGDAI combination for patients with active ulcerative colitis: A randomized double-blinded placebo-controlled clinical trial. Inflammatory Bowel Diseases, 29(Supplement_1). https://doi.org/10.1093/ibd/izac247.019
  3. Bommelaer, G., Laharie, D., Nancey, S., Hebuterne, X., Roblin, X., Nachury, M., Peyrin-Biroulet, L., Fumery, M., Richard, D., Pereira, B., Goutte, M., Buisson, A., Coban, D., Dodel, M., Goutorbe, F., Allimant, C., Reymond, M., Dapoigny, M., Rouquette, O., … Brazier, F. (2020). Oral curcumin no more effective than placebo in preventing recurrence of Crohn’s disease after surgery in a randomized controlled trial. Clinical Gastroenterology and Hepatology, 18(7). https://doi.org/10.1016/j.cgh.2019.08.041
  4. Carroll, R. E., Benya, R. V., Turgeon, D. K., Vareed, S., Neuman, M., Rodriguez, L., Kakarala, M., Carpenter, P. M., McLaren, C., Meyskens, F. L., Jr, & Brenner, D. E. (2011). Phase IIa clinical trial of curcumin for the prevention of colorectal neoplasia. Cancer prevention research (Philadelphia, Pa.), 4(3), 354–364. https://doi.org/10.1158/1940-6207.CAPR-10-0098
  5. Duvoix, A., Blasius, R., Delhalle, S., Schnekenburger, M., Morceau, F., Henry, E., Dicato, M., & Diederich, M. (2005). Chemopreventive and therapeutic effects of curcumin. Cancer letters, 223(2), 181–190. https://doi.org/10.1016/j.canlet.2004.09.041
  6. Hanai, H., Iida, T., Takeuchi, K., Watanabe, F., Maruyama, Y., Andoh, A., Tsujikawa, T., Fujiyama, Y., Mitsuyama, K., Sata, M., Yamada, M., Iwaoka, Y., Kanke, K., Hiraishi, H., Hirayama, K., Arai, H., Yoshii, S., Uchijima, M., Nagata, T., & Koide, Y. (2006). Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 4(12), 1502–1506. https://doi.org/10.1016/j.cgh.2006.08.008
  7. Holt, P. R., Katz, S., & Kirshoff, R. (2005). Curcumin therapy in inflammatory bowel disease: a pilot study. Digestive diseases and sciences, 50(11), 2191–2193. https://doi.org/10.1007/s10620-005-3032-8
  8. Jobin, C., Bradham, C. A., Russo, M. P., Juma, B., Narula, A. S., Brenner, D. A., & Sartor, R. B. (1999). Curcumin blocks cytokine-mediated NF-kappa B activation and proinflammatory gene expression by inhibiting inhibitory factor I-kappa B kinase activity. Journal of immunology (Baltimore, Md. : 1950), 163(6), 3474–3483.
  9. Kedia, S., Bhatia, V., Thareja, S., Garg, S., Mouli, V. P., Bopanna, S., Tiwari, V., Makharia, G., & Ahuja, V. (2017). Low dose oral curcumin is not effective in induction of remission in mild to moderate ulcerative colitis: Results from a randomized double blind placebo controlled trial. World Journal of Gastrointestinal Pharmacology and Therapeutics, 8(2), 147–155. https://doi.org/10.4292/wjgpt.v8.i2.147
  10. Lang, A., Salomon, N., Wu, J. C., Kopylov, U., Lahat, A., Har-Noy, O., Ching, J. Y., Cheong, P. K., Avidan, B., Gamus, D., Kaimakliotis, I., Eliakim, R., Ng, S. C., & Ben-Horin, S. (2015). Curcumin in Combination With Mesalamine Induces Remission in Patients With Mild-to-Moderate Ulcerative Colitis in a Randomized Controlled Trial. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 13(8), 1444–9.e1. https://doi.org/10.1016/j.cgh.2015.02.019
  11. Lao, C. D., Ruffin, M. T., 4th, Normolle, D., Heath, D. D., Murray, S. I., Bailey, J. M., Boggs, M. E., Crowell, J., Rock, C. L., & Brenner, D. E. (2006). Dose escalation of a curcuminoid formulation. BMC complementary and alternative medicine, 6, 10. https://doi.org/10.1186/1472-6882-6-10
  12. Li, S. Q., Zhu, X. R., Qin, B. C., & Chen, M. B. (2025). Curcumin in colorectal cancer: mechanistic insights, pharmacological limitations, and translational perspectives. Frontiers in pharmacology, 16, 1667731. https://doi.org/10.3389/fphar.2025.1667731
  13. Masoodi, M., Mahdiabadi, M. A., Mokhtare, M., Agah, S., Kashani, A. H. F., Rezadoost, A. M., … Asl, M. N. (2018). The efficacy of curcuminoids in improvement of ulcerative colitis symptoms and patients’ self-reported well-being: A randomized double-blind controlled trial. Journal of Cellular Biochemistry, 119, 9552–9559. https://doi.org/10.1002/jcb.27273
  14. National Institute of Diabetes and Digestive and Kidney Diseases. (2012–2025). Turmeric. In LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. National Center for Biotechnology Information. https://www.ncbi.nlm.nih.gov/books/NBK548561/
  15. Ojo, O. A., Adeyemo, T. R., Rotimi, D., Batiha, G. E., Mostafa-Hedeab, G., Iyobhebhe, M. E., Elebiyo, T. C., Atunwa, B., Ojo, A. B., Lima, C. M. G., & Conte-Junior, C. A. (2022). Anticancer properties of curcumin against colorectal cancer: A review. Frontiers in Oncology, 12, 881641. https://doi.org/10.3389/fonc.2022.881641
  16. Perkins, S., Verschoyle, R. D., Hill, K., Parveen, I., Threadgill, M. D., Sharma, R. A., Williams, M. L., Steward, W. P., & Gescher, A. J. (2002). Chemopreventive efficacy and pharmacokinetics of curcumin in the min/+ mouse, a model of familial adenomatous polyposis. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 11(6), 535–540.
  17. Sadeghi, N., Mansoori, A., Shayesteh, A., & Hashemi, S. J. (2020). The effect of curcumin supplementation on clinical outcomes and inflammatory markers in patients with ulcerative colitis. Phytotherapy Research, 34, 1123–1133. https://doi.org/10.1002/ptr.6581
  18. Shapira, S., Leshno, A., Katz, D., Maharshak, N., Hevroni, G., Jean-David, M., et al. (2018). Of mice and men: A novel dietary supplement for the treatment of ulcerative colitis. Therapeutic Advances in Gastroenterology, 11, 1756283X17741864. https://doi.org/10.1177/1756283X17741864
  19. Singla, V., Pratap Mouli, V., Garg, S. K., Rai, T., Choudhury, B. N., Verma, P., Deb, R., Tiwari, V., Rohatgi, S., Dhingra, R., Kedia, S., Sharma, P. K., Makharia, G., & Ahuja, V. (2014). Induction with NCB-02 (curcumin) enema for mild-to-moderate distal ulcerative colitis – a randomized, placebo-controlled, pilot study. Journal of Crohn’s & colitis, 8(3), 208–214. https://doi.org/10.1016/j.crohns.2013.08.006
  20. Sugimoto, K., Ikeya, K., Bamba, S., Andoh, A., Yamasaki, H., Mitsuyama, K., Nasuno, M., Tanaka, H., Matsuura, A., Kato, M., Ishida, N., Tamura, S., Takano, R., Tani, S., Osawa, S., Nishihira, J., & Hanai, H. (2020). Highly bioavailable curcumin derivative ameliorates Crohn’s disease symptoms: A randomized, double-blind, multicenter study. Journal of Crohn’s and Colitis, 14(12), 1693–1701. https://doi.org/10.1093/ecco-jcc/jjaa097
  21. Vadhan-Raj, S., Weber, D. M., Wang, M., Giralt, S. A., Thomas, S. K., Alexanian, R., Zhou, X., Patel, P., Bueso-Ramos, C. E., Newman, R. A., & Aggarwal, B. B. (2007). Curcumin downregulates NF-KB and related genes in patients with multiple myeloma: Results of a phase I/II study. Blood, 110(11), 1177–1177. https://doi.org/10.1182/blood.v110.11.1177.1177

 

Written by: Aubrey Lee, Dietitian; Gina Almasan, Dietitian; Genelle Lunken, Dietitian, PhD